Latest SAS® Drug Development helps clinical research organizations speed new treatments to market
New workflow facilitates global collaboration and compliance
The next generation of SAS® Drug Development is now available, speeding clinical trial data analysis for pharmaceutical, biotechnology and medical device manufacturers. Ultimately shortening time to market for new products, the enhanced software from health analytics leader SAS represents the industry’s gold standard for analytics and the knowledge gained from more than 10 years of field-proven product experience.
SAS Drug Development offers:
- Secure, centralized access to large, complex data
- Streamlined processes that enable multiple analyses with complex project management
- Early visibility and quicker decisions by clinical researchers
- Shorter development cycles, which reduce costs and get product to market faster
The latest version of SAS Drug Development – used by more than 40 customers, including Daiichi Sankyo, Astellas Pharma and Shire – now incorporates an integrated workflow to improve project oversight, automated process orchestration, and an enhanced programming environment for seasoned SAS experts.
"The ability to collect, analyze, share, and act quickly on insights extracted from data is a strategic differentiator between industry leaders and laggards," said Alan S. Louie, Research Director, IDC Health Insights. "The new innovations in SAS Drug Development clearly show a strong, continued commitment to the rapidly changing health care industry and ensure that SAS continues as a core contributor."
New features and functionality
SAS Drug Development helps organizations better monitor statistical programming and data management resources. Users can also implement non-programming clinical development processes and associated standard operating procedures within the workflow engine, harmonizing organizational, project, group or even an individual's activities.
"One of the key benefits of SAS is that it standardizes the process for receiving and storing data as well as making data available to the users," said Bernd Doetzkies, Director of Informatics, Daiichi Sankyo. "Our vision for the clinical data repository model has been expanded, and we see SAS Drug Development as a hub to our interoperable platform environment of transformational information systems."
Matt Gross, Director of the Health and Life Sciences Global Practice for SAS, noted, "SAS Drug Development's multitude of satisfied users has helped evolve the product throughout the decade. Their feedback, along with input from industry and thought leaders, is invaluable for meeting the increasing demands faced by our customers."
What does SAS® Drug Development do?
The solution helps organizations make informed clinical and business decisions; streamline and optimize analysis and reporting processes; assess safety and efficacy more effectively; and improve collaboration with business partners and regulatory authorities. It eases analysis and reporting for single trials as well as aggregated clinical data assets across multiple trials or therapies.
SAS will demonstrate its life sciences products in Booth 1625 during the DIA 2012 Annual Meeting in Philadelphia on June 25-27.
SAS in Health Analytics
SAS is the industry leader in health analytics software and services, delivering best-in-class solutions for improving medical care, strengthening financial performance, deepening customer relationships and pursuing medical innovations. AstraZeneca, Eli Lilly and Company, and McKesson are among the leading life sciences companies that use SAS. Visit SAS® for Life Sciences for more information.
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions, SAS helps customers at more than 70,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world THE POWER TO KNOW®.